SILKBridge, a silk-based graft, is a tissue-engineered technology based on pure silk fibroin. It has the potential to show an optimized balance between biomechanical and biological properties, complementing the high strength of native silk fibers and the enhanced biomimicry of electrospun silk. It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect and is anticipated to be available for clinical use in 2023.

“We are very excited about the impact SILKBridge is anticipated to have on treatment of peripheral nerve injuries. This is truly a life-changing innovation that represents our commitment to disrupting the restorative surgical market,” said Gabriele Grecchi, CEO and co-founder of KLISBio.

KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications. Silk fibroin is also fully biocompatible and promotes cell proliferation by stimulating in-vivo tissue regeneration.

“Our goal is to challenge the status quo in regenerative medicine by leveraging silk as a powerful and biocompatible scaffold material, targeting different clinical indications in the orthopedic, vascular and drug release markets via several technology platforms,” added Grecchi.

As well as being powered by an international group of world leaders in medtech, KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.